Livedoid vasculitis - Васкулитҳои Livedoid
Васкулитҳои Livedoid (Livedoid vasculitis) як бемории музмини пӯст аст, ки асосан дар занони ҷавон то миёнасол мушоҳида мешавад. Як мухтасаре, ки барои тавсифи хусусиятҳои он истифода мешавад, "Захми пурпури дарднок бо шакли ретикулярии узвҳои поёнӣ" (PURPLE) мебошад. Он бо як қатор бемориҳо, аз ҷумла гипертонияи музмини венаҳо ва варикозҳо алоқаманд аст.
☆ Дар натиҷаҳои соли 2022 Stiftung Warentest аз Олмон, қаноатмандии истеъмолкунандагон аз ModelDerm нисбат ба машваратҳои пулакии телетиб танҳо каме пасттар буд.
Он метавонад бо дард ҳамроҳӣ кунад.
References
Livedoid vasculopathy як ҳолати нодири пӯст аст, ки бо захмҳои дардоваре, ки дар пойҳои поён бармегарданд, тавсиф мешавад.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy як бемории нодири пӯст аст, ки боиси пайдоиши захми такроршаванда дар пойҳои поён мегардад ва дар паси он захмҳои саманд, ки бо номи атрофии бланш маъруфанд, боқӣ мемонад. Дар ҳоле ки сабаби дақиқ то ҳол норавшан аст, он боварӣ дорад, ки афзоиши лахташавии хун (hypercoagulability) омили асосӣ аст ва илтиҳоб нақши дуюмдараҷа мебозад. Омилҳое, ки ба лахташавӣ мусоидат мекунанд, инҳоянд - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Дар биопсия, ин ҳолат лахтаҳои хун дар дохили рагҳо, ғафсшавии деворҳои рагҳо ва ҷароҳатҳоро нишон медиҳад. Табобат як равиши бисёрҷанбаро дар бар мегирад, ки ба пешгирии лахтаҳои хун бо доруҳо, ба монанди доруҳои зидди тромбоситҳо, лоғарҳои хун ва терапияи фибринолитикӣ тамаркуз мекунад. Барои ин ҳолати пӯст доруҳои гуногунро истифода бурдан мумкин аст - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy як ҳолати нодир аст, ки дар ҳарду по захмҳо пайдо мешаванд. Ташаккули лахтаҳои хун дар рагҳои хурди хун аз сабаби зиёд шудани лахташавӣ ва коҳиши шикасти лахта дар баробари осеби пӯшиши рагҳо ба вуҷуд омадааст. Ин бештар дар духтарон, махсусан аз 15 то 50-сола маъмул аст. Даст кашидан аз тамокукашӣ, нигоҳубини захмҳо ва истифодаи доруҳо ба монанди лоғаркунандаи хун ва доруҳои зидди тромбоситҳо самаранок буд.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
